Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential

Investing.com -- Adyen (AS:ADYEN) and AstraZeneca (NASDAQ:AZN) have been named among TD Cowen’s latest Best Ideas, highlighting their strong growth potential and competitive positioning in their respective industries. 

Both companies stand out for their ability to navigate macroeconomic challenges while delivering above-average financial performance and expansion strategies.

AstraZeneca’s performance in 2024 was underpinned by continued strength in its oncology and rare disease portfolio, leading to an 18% increase in revenue, which reached $54.08 billion. 

The company projects further growth in 2025, with revenue expected to rise 5% to $56.87 billion. 

Its earnings per share stood at $8.21 in 2024, marking a 13% increase from the previous year, with an expected further rise of 6% to $8.70 in 2025. 

AstraZeneca’s pipeline remains a key driver of long-term value, with a revenue growth forecast of 7% annually through 2030, outpacing the 4% industry average. 

The pharmaceutical giant’s innovation in oncology, respiratory, and metabolic treatments is expected to support an 11% compound annual growth rate in EPS over the same period.

Adyen continues to make strides in expanding its market share, leveraging its modern tech stack and integrated banking licenses.

The global payments technology company reported revenue of €1.99 billion in 2024 and expects to see a significant increase to €2.47 billion in 2025. 

Adyen’s EBITDA is projected to grow at a high-20s to low-30s annual rate, with margins already surpassing its 2026 target of 50%. 

The company’s ability to scale through its land-and-expand strategy, coupled with strong client additions and continued innovation, positions it well for sustained long-term growth. 

Adyen’s focus on payment efficiency and cost reduction for its clients has allowed it to differentiate itself from legacy players in the payments space.

Both AstraZeneca and Adyen have demonstrated resilience amid broader economic uncertainties. 

AstraZeneca has navigated regulatory risks in China while maintaining strong profitability, and Adyen has managed to balance expansion and efficiency despite competitive pressures in the payments industry. 

AstraZeneca is trading at 17.8 times its estimated 2025 earnings, with a price target of $95, reflecting a valuation of 19.7 times projected 2026 EPS. 

Adyen, meanwhile, trades at 21.5 times forward EBITDA, with a price target of €2,103, a level seen as attractive compared to historical valuations.